TRexBio Reports New TRB-061 Data for Atopic Dermatitis
SOUTH SAN FRANCISCO, Calif., May 7, 2026 TRexBio announced new late-breaking translational and preclinical data supporting TNFR2 agonism as...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
SOUTH SAN FRANCISCO, Calif., May 7, 2026 TRexBio announced new late-breaking translational and preclinical data supporting TNFR2 agonism as...
IRVING, Texas, April 9, 2026 Revision Skincare® has announced the publication of two peer-reviewed clinical studies in the Journal...
San Francisco, USA | March 28, 2026 Phase 2b Data Demonstrates Strong Clinical Efficacy Nektar Therapeutics has announced compelling...
Sacramento, California | February 19, 2026 — KilgourMD announced results from an independent Phase II clinical trial evaluating its...
